(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
This is an open-label, two-part Phase 2 study investigating CGT9486 for the treatment of patients with Advanced Systemic Mastocytosis (AdvSM), including patients with Aggressive SM (ASM), SM with Associated Hematologic Neoplasm (SM-AHN), and Mast Cell Leukemia (MCL).
Advanced Systemic Mastocytosis (AdvSM)|SM With an Associated Hematologic Neoplasm (SM-AHN)|Mast Cell Leukemia (MCL)|Aggressive Systemic Mastocytosis (ASM)
DRUG: bezuclastinib
Part I: Identify clinically active and tolerable exposures of bezuclastinib in patients with AdvSM, 18 months|Part II: - Determine efficacy of bezuclastinib as measured by mIWG Objective Response Rate (ORR) - Confirm the exposure-response relationship of bezuclastinib, 18 months
Pure Pathologic Response (PPR), Months, 18 months|Safety of CGT9486 as assessed by incidence of Adverse Events (AEs), Incidence of AEs according to CTCAE version 5.0 or higher, 18 months|To determine the effects of bezuclastinib on mutation allele burden., Percentage change in KIT D816V, 18 months|To determine the effects of bezuclastinib on serum tryptase., Percentage change in Serum Tryptase, 18 months|To assess the pharmacokinetics of bezuclastinib in subjects with AdvSM., Percentage change in plasma concentrations of bezuclastinib, 18 months|Change from baseline in histopathologic findings in blood and bone marrow, Percentage change in mast cell infiltration in the bone marrow and percentage change in eosinophilia and monocytosis in the blood, 18 months|Change in spleen and liver volume by imaging, Percentage change, 18 months|Duration of Response (DOR), Months, 18 months|Time to Response (TTR), Months, 18 months|Progression Free Survival (PFS), Months, 18 Months|Overall Survival (OS), Months, 18 months
This is an open-label, two-part Phase 2 study investigating CGT9486 for the treatment of patients with Advanced Systemic Mastocytosis (AdvSM), including patients with Aggressive SM (ASM), SM with Associated Hematologic Neoplasm (SM-AHN), and Mast Cell Leukemia (MCL).